Nasdaq

GE Healthcare Receives FDA Approval for Change in Contraindications in Prescribing Information for OptisonTM

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- GE Healthcare announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to remove hypersensitivity to ‘blood and blood ...
Business Wire

GE Healthcare Medical Diagnostics Relaunches Optison™ Contrast Agent in Europe | Business Wire

AMERSHAM, England-- (BUSINESS WIRE)--GE Healthcare’s Medical Diagnostics division announced the market reintroduction of Optison™ (Perflutren Protein-Type A Microspheres Injectable Suspension, USP), a ...
Monthly Prescribing Reference

FDA Approves Change in Contraindications for Optison

The removal of the contraindication to screen for hypersensitivity to blood and blood products is expected to improve workflow efficiency for health care professionals. The Food and Drug ...
Nasdaq

GE HealthCare Stock May Gain as FDA Approves Optison for Pediatric Use

GE HealthCare Technologies Inc. GEHC recently announced FDA approval for Optison, its polyethylene glycol (PEG)-free ultrasound enhancing agent, for use in pediatric patients. This milestone expands ...